Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial

CONCLUSIONS: Third-line regimens comprising of RAL, DRV/r and/or ETR were very well tolerated and had high rates of durable virologic suppression among PLWH in LMICs who were failing on second-line PI-based ART prior to the availability of dolutegravir.PMID:36039892 | DOI:10.1002/jia2.25905

Source: Journal of the International AIDS Society - August 30, 2022 Category: Infectious Diseases Authors: Anchalee Avihingsanon Michael D Hughes Robert Salata Catherine Godfrey Caitlyn McCarthy Peter Mugyenyi Evelyn Hogg Robert Gross Sandra W Cardoso Aggrey Bukuru Mumbi Makanga Sharlaa Badal-Aesen Vidya Mave Beatrice Wangari Ndege Sandy Nerette Fontain Wadzan Source Type: research